Moxifloxacin Hydrochloride Monohydrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

89 API Suppliers, 24 USDMF, 24 CEP/COS, 7 JDMF, 16 EU WC, 18 KDMF, 19 NDC API, 47 Listed Suppliers

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

150 FDF Dossiers, 32 FDA Orange Book, 82 Europe, 14 Canada, 2 South Africa, 20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 Rochem International Inc, 7 SPI Pharma, 1 Pharm-RX Chemical, 5 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 3 Kirsch Pharma, 1 Panvo Organics, 1 Cerata Pharmaceuticals LLP, 4 Dr. Paul Lohmann GmbH & Co. KGaA, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 12 BASF, 1 CD Formulation, 2 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 1 Finar, 10 Gangwal Chemicals, 2 Gloria Interchem, 1 Huzhou Sunflower Pharmaceutical, 5 Ideal Cures, 4 Ingredion Pharma Solutions, 21 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 1 Neelkanth MineChem, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 27 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

61 Fillers, Diluents & Binders, 46 Coating Systems & Additives, 26 Disintegrants & Superdisintegrants, 24 Controlled & Modified Release, 24 Direct Compression, 23 Thickeners and Stabilizers, 23 Solubilizers, 21 Lubricants & Glidants, 20 Film Formers & Plasticizers, 20 Granulation, 19 Parenteral, 15 Co-Processed Excipients, 15 Topical, 12 Taste Masking, 10 Chewable & Orodispersible Aids, 10 API Stability Enhancers, 9 Emulsifying Agents, 6 Rheology Modifiers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 4 Vegetarian Capsules, 2 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

3 Data Compilation #PharmaFlow, 20 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions, 4 Regulatory FDF Prices, 4 Annual Reports

MARKET PLACE

29 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 18 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 2 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

Moxifloxacin Hydrochloride Monohydrate

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Seppic

filter Capability Reset all filters

filter Country Reset all filters

01

Seppic

SEPIFILM CLASSIC RANGE

PCC

Not Confirmed

02

Seppic

SEPIFILM PW RANGE

PCC

Not Confirmed

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Looking for Moxifloxacin Hydrochloride Monohydrate? Find Coloring Agents used in Moxifloxacin Hydrochloride Monohydrate to address drug delivery challenges on PharmaCompass.

Moxifloxacin Hydrochloride Monohydrate

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

89 API Suppliers

24 USDMF

24 CEP/COS

7 JDMF

16 EU WC

18 KDMF

19 NDC API

47 Listed Suppliers

DEVELOPMENTS

3 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

150 FDF Dossiers

32 FDA Orange Book

82 Europe

14 Canada

2 South Africa

20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

1 Minakem

2 Rochem International Inc

7 SPI Pharma

1 Pharm-RX Chemical

5 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

6 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

3 Kirsch Pharma

1 Panvo Organics

1 Cerata Pharmaceuticals LLP

4 Dr. Paul Lohmann GmbH & Co. KGaA

1 ACG Worldwide

8 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Avesta Pharma

12 BASF

1 CD Formulation

2 Clariant

10 Corel Pharma Chem

6 DFE Pharma

1 Esteem Industries

1 Finar

10 Gangwal Chemicals

2 Gloria Interchem

1 Huzhou Sunflower Pharmaceutical

5 Ideal Cures

4 Ingredion Pharma Solutions

21 Kerry

3 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

11 Microlex e.U

1 Nanjing Bold Chemical

1 Neelkanth MineChem

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

3 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

27 Roquette

13 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

TABLET;ORAL - EQ 400MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons